Eligibility can change based on how the prescription is categorized and how your plan administrator reviews the claim
Current Regulatory Status in the UK and Globally As of mid-2025, retatrutide has no marketing authorisation in the UK, EU, or US
And of course, the shortage of the newest, most expensive GLP-1 products has also dissipated
Semaglutide still the GLP-1 heavyweight If Novo Nordisks semaglutide were counted as a single drug, it would be second bestselling drug of 2023, with total sales of $19.93 billion compared to Keytrudas (pembrolizumab) $25.01 billion
Every 4 weeks, the dose is typically increased until you reach the maintenance dose
Future implications of sublingual formulations of GLP-1 receptor agonists As mentioned above, GLP-1 receptor agonists are approved for the treatment of T2D and (sometimes off label) used for the treatment of obesity